Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q13257
UPID:
MD2L1_HUMAN
Alternative names:
Mitotic arrest deficient 2-like protein 1
Alternative UPACC:
Q13257; Q53F56; Q548X9; Q6IRW7; Q8IZX3
Background:
Mitotic spindle assembly checkpoint protein MAD2A, also known as Mitotic arrest deficient 2-like protein 1, plays a crucial role in cell division. It ensures that chromosomes are correctly aligned before a cell proceeds from metaphase to anaphase, by forming a complex that inhibits premature separation. This process is vital for genetic stability and cell viability.
Therapeutic significance:
Understanding the role of Mitotic spindle assembly checkpoint protein MAD2A could open doors to potential therapeutic strategies. Its pivotal function in cell cycle regulation highlights its potential as a target in cancer therapy, where cell division often goes awry.